| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Deferred offering costs | NaN | 253,556 | 255,853 | 153,032 |
| Cash | 82,200 | 42,854 | 38,118 | 147,192 |
| Prepaids and other current assets | 14,175 | 18,180 | 26,560 | 40,156 |
| Total current assets | 96,375 | 314,590 | 320,531 | 340,380 |
| Fixed assets, net | 56,766 | 60,484 | 62,507 | 78,083 |
| Right-of-use asset, net | 6,678 | 16,527 | 26,180 | 35,640 |
| Total non-current assets | 63,444 | 77,011 | 88,687 | 113,723 |
| Total assets | 159,819 | 391,601 | 409,218 | 454,103 |
| Accounts payable | 630,315 | 546,873 | 472,551 | 383,256 |
| Accrued expenses-Nonrelated Party | 319,169 | 286,706 | 263,026 | 223,034 |
| Accrued expenses-Related Party | 184,901 | 159,636 | 130,462 | 59,901 |
| Lease liability - long term | NaN | NaN | NaN | 0 |
| Current maturities of notes payable | NaN | NaN | 315,678 | 275,733 |
| Total non-current liabilities | NaN | NaN | NaN | 0 |
| Current maturities of notes payable, net of discounts | 293,513 | 310,629 | 1,303,832 | 1,208,235 |
| Lease liabilities - current | 6,842 | 16,939 | 26,838 | 36,545 |
| Total current liabilities | 1,434,740 | 1,320,783 | 2,512,387 | 2,186,704 |
| Total notes payable | 453,272 | NaN | NaN | NaN |
| Less discounts on notes payable | 36,659 | NaN | NaN | NaN |
| Notes payable, net of discounts | 416,613 | NaN | NaN | NaN |
| Less current maturities | 293,513 | NaN | NaN | NaN |
| Notes payable, net of current | 123,100 | 118,100 | NaN | NaN |
| Total convertible notes payable | NaN | 1,306,582 | NaN | NaN |
| Less unamortized debt discounts | NaN | 2,375 | NaN | NaN |
| Convertible notes payable, net of current and discounts | 1,384,582 | 1,304,207 | NaN | NaN |
| Total liabilities | 2,942,422 | 2,743,090 | 2,512,387 | 2,186,704 |
| Series b convertible preferred stock, 0.001 par value, 1,500,000 shares authorized 333,600 shares issued and outstanding as of march 31, 2026 and september 30, 2025 | 333,600 | 333,600 | 333,600 | 333,600 |
| Preferred stock, value-Series AConvertible Preferred Stock | 1,048 | 1,048 | 1,048 | 1,048 |
| Preferred stock value-Series CConvertible Preferred Stock | NaN | NaN | 1 | NaN |
| Preferred stock, value-Series DPreferred Stock | 700 | 700 | NaN | 0 |
| Preferred stock value-Series DConvertible Preferred Stock | NaN | NaN | 390 | NaN |
| Preferred stock, value-Series CPreferred Stock | 1 | 1 | NaN | 1 |
| Common stock, 0.001 par value, 880,000,000 shares authorized 163,895,977 and 147,121,825 shares issued and outstanding as of march 31, 2026 and september 30, 2025, respectively | 163,895 | 155,521 | 147,121 | 145,121 |
| Additional paid-in capital | 21,410,232 | 21,328,606 | 21,063,998 | 20,878,541 |
| Accumulated deficit | -24,692,079 | -24,170,965 | -23,649,327 | -23,090,912 |
| Total stockholders deficit | -3,116,203 | -2,685,089 | -2,436,769 | -2,066,201 |
| Total liabilities and stockholders deficit | 159,819 | 391,601 | 409,218 | 454,103 |
Hypha Labs, Inc. (FUNI)
Hypha Labs, Inc. (FUNI)